Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design.

Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Collaborator: Lundbeck Israel
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Patients suffering from MDD, excluding a depressive episode of Bipolar Disorder.

• The depressive episode is not secondary to a general medical condition or substance abuse.

• Ages between 18-65 years old.

• Patients receiving other medications must be on a stable dosage for one month before entering the trial, including hypnotics.

• Able to understand and sign an informed consent form.

Exclusion Criteria:

• Patients suffering from sleep disturbances due to a physical condition (COPD, sleep apnea or essential insomnia preceding the diagnosis of depression).

• Patients suffering from an unstable clinically significant medical condition (cardiovascular, endocrine, nutritional, hepatic, urinary).

• Patients suffering from a malignancy or neuro-degenerative such as Parkinsons' disease

• Patients suffering from a clinically significant psychiatric psychotic disease, as judged by DSM-IV criteria, such as schizophrenia or acute psychosis.

• Patients experiencing severe withdrawal symptoms following a discontinuation of hypnotic drugs, upon entry into the baseline phase.

• History of drug or alcohol dependence within the last year.